Table 3 Ongoing clinical trials of BTKi combinations for treatment of patients with WM.
From: Managing Waldenström’s macroglobulinemia with BTK inhibitors
Trial | Treatments (class) | Description | Estimated primary completion date |
|---|---|---|---|
NCT04260217 | Ibrutinib and APG-2575 (BCL2 inhibitor) | Phase Ib /II, open label | September 2022 |
NCT03679624 | Ibrutinib and daratumumab (anti-CD38 monoclonal antibody) | Phase II, open label | October 2022 |
NCT03620903 | Ibrutinib and bortezomib (proteasome inhibitor), and rituximab | Phase II, open label | December 2022 |
NCT04274738 | Ibrutinib and mavorixafor (CXCR4 inhibitor) | Phase I, open label | January 2023 |
NCT03225716 | Ibrutinib and ulocuplumab (anti-CXCR4 monoclonal antibody) | Phase I/II, open label | January 2023 |
NCT04463953 | Zanubrutinib, ixazomib (proteasome inhibitor), and dexamethasone | Phase II, open label | May 2023 |
NCT04273139 | Ibrutinib and venetoclax (BCL2 inhibitor) | Phase II, open label | June 2023 |
NCT04624906 | Acalabrutinib, bendamustine, and rituximab | Phase II, open label | December 2024 |
NCT03506373 | Ibrutinib and ixazomib (proteasome inhibitor) | Phase II, open label | May 2025 |
NCT04263480 | Ibrutinib and carfilzomib (proteasome inhibitor) | Phase II, open label | February 2028 |
